Hemophilia Factor Dose

CSL Behring Receives EU Orphan Drug Designations for rVIIa-FP for Hemophilia A ...

Under these designations European Medicines Agency (EMA) will also provide CSL Behring with development assistance and with reductions in certain regulatory fees.

"CSL Behring welcomes Orphan Drug Designation for rVIIa-FP as support of our ongoing commitment to developing, manufacturing and marketing products for the treatment of rare and serious diseases, such as hemophilia with inhibitors," said .

By providing incentives to the pharmaceutical industry, the EU legislative framework for orphan medicines encourages the development of products intended to diagnose, prevent and treat life-threatening or chronically-debilitating conditions that impact up to 5 in 10,000 people in the European Union. The initiative helps improve access to quality medical care for patients who have rare diseases for which there are few, if any, approved treatments.

About Hemophilia

Hemophilia is an inherited bleeding disorder characterized by prolonged or spontaneous bleeding, especially into the muscles, joints, or internal organs. The disease is caused by deficient or defective blood coagulation proteins known as factor VIII or IX. The most common form of the disease is hemophilia A, or classic hemophilia, in which the clotting factor VIII is either deficient or defective. Hemophilia B is characterized by deficient or defective factor IX. Hemophilia A affects approximately 1 in 5,000 to 10,000 people. Hemophilia B affects approximately 1 in 25,000 to 50,000 people. The recommended treatment for patients who are factor deficient is to treat by replacement factor therapy.

Some patients develop inhibitors, factor VIII or IX neutralizing antibodies which render further replacement therapy ineffective. It has been reported that up to 33% of all severe hemophilia A and up to 6% of all severe hemophilia B patients develop inhibitors.

Natural Weight Loss | Prolor Biotech: Interim Phase 2 Data Promising

Upcoming Events – Full Phase 2 human expansion hormone sip trimming investigate (hGH-CTP) results Q3 2011, arising of Phase 3 in adults (2012), and Phase 2 in young kids (Q3-Q4 2011).

Prolor Biotech ( PBTH ) – formed in Nes-Ziona, Israel, engages in the development and commercialization of bio-better proteins and peptides. Utilizing their exclusive CTP extended recombinant proteins, the firm aims to precedence its technology stage to supply new, extended versions of stream recombinant proteins in a safe, efficacious, and arguable manner. By utilizing this strategy, Prolor hopes to accomplish reduction costly and faster clinical trials given endpoints and investigate protocols will be the same as those used for existing therapies. Additionally, Prolor believes its plan of targeting healing proteins already granted by the FDA, with proven safety and efficacy, allows them to descend the danger form of their exclusive development portfolio compared to de novo healing protein development. The lead candidate, permanent human expansion hormone, is now in Phase 2 trials for hGH insufficient adults.

Interim Phase 2 Data – Recently, Prolor expelled meantime information on their continuing Phase 2 trial. The certain meantime information from 34 patients follows PROLOR ‘s statement in February that hGH-CTP demonstrated a great safety profile, as fixed in a examination of meantime information by the eccentric Data and Safety Monitoring Board. Still not complete, the investigate will enroll up to roughly 65 patients total.

Designed as an open label, switchover hearing in responding adult patients (i.e. normal IGF-1 levels, the clinically agreed biomarker for hGH levels) now on every day injections of hGH, patients were placed in to a of 4 dosing cohorts. Receiving possibly 30%, 45%, or 100% of the accumulative weekly complete of hGH, patients were injected once weekly for a month and their IGF-1 levels monitored. A fourth initial conspirator was given a 100% accumulative sip every other week. The objective of the investigate is to establish the sip ranges that supply hGH insufficient adults with IGF-1 levels inside of the normal operation (+/- 2 typical deviations, SD).

The rough information (30% and 45% cohorts) show that Prolor ‘s hGH-CTP has a half-life roughly 10 overlay longer than blurb hGH, providing the aptitude to reinstate every day injections with weekly, at a minimum. Delving more deeply in to the numbers, at the 45% dosing range, patients ‘ IGF-1 levels were inside of +/- 2 SD, the operation endocrinologists look for, 100% of the time over the 7 days. Furthermore, IGF-1 levels stayed inside of a tighter range, +/- 1.5 SD 93% of the time. Based on these results alone, it is expected that Prolor could use this sip to beginner a larger, Phase 3 trial. In the 30% accumulative dosing arm, the results were really ominous and positive. While staying in the operation of +/- 2 SD 64% of the time, and the narrower +/- 1 SD 43% of the time, the IGF-1 levels never dipped next – 2.5 SD. This provides efficient information, as a few endocrinologists pick descend levels. Importantly, no spike of IGF-1 was celebrated at the beginning of the week in possibly cohort. As with the Phase 1 trial, safety and tolerability remained glorious with no antibodies formed.

Stoelting's anesthesia and co-existing disease

Textbook of Hemophilia

Inhibitors in Patients with Haemophilia

Irwin and Rippe's intensive care medicine

34th Hemophilia Symposium, Hamburg 2003 : presentation: HIV infection and epidemiology; management of bleedings in hemophiliacs with inhibitors; orthopedic problems and therapy in hemophiliacs; therapy with protein c; pediatric hemostaseology; free lectures